Ian Bezek

Ian Bezek

Ian Bezek earned his economics degree from Colorado State University in 2010. He then worked as an analyst for Kerrisdale Capital, a New York City-based activist hedge fund, from 2011-13. Since then, Ian has focused on finding under-the-radar investment opportunities, particularly overseas. To that end, he taught himself Spanish and has lived in Mexico and Argentina among other countries. He currently resides in Colombia with his family.

You can interact with Ian on Twitter.

Recent Articles

Shiba Inu Still Has Nothing Other than Fading Meme Status

January's crypto crash is only the latest problem for struggling Shiba Inu. Ultimately, the token just doesn't do enough to stand out among cryptocurrencies.

7 Russian Stocks at Risk of Being Roiled By the Ukraine Conflict

Russia is flexing its military muscle once again. This could put these seven Russian stocks in serious jeopardy.

A Buyout May Be the Best Hope for Clover Health Now

The situation behind CLOV stock is spiraling from bad to worse. A sale of the company may be the only option to keep Clover Health running.

Solana Looks to Bounce Back After Dreadful January

Solana has built one of crypto's most successful and useful platforms. But it must fix its network stability issues before it's too late.

7 Best Renewable Energy Stocks to Buy in Q1

Many investors have given up on renewable energy stocks. That creates some opportunities to buy sector leaders at discounted prices.

QuantumScape: Hindered by Lack of Near-Term Catalysts

A cheaper price makes QS stock a little more attractive. Still, QuantumScape is hard to own given its lack of catalysts and uncertain long-term capabilities.

SoFi Gets Bank License, But That’s Not Necessarily a Good Thing

SoFi has held up alright given the rough market conditions. However, don't count on a bank license causing SOFI stock to recover.

Why a Co-Founder of Facebook Is Buying Millions of Shares of Asana

A powerful billionaire is buying millions of ASAN stock shares right now. It might not be a bad idea to follow his lead.

DraftKings: Rough Earnings Now, But There’s Light on the Horizon

As fears around operating losses growth, DKNG stock has collapsed. At this price, it just might be worth a roll of the dice.

Novavax Can Still Succeed, But It’s Facing High Risks

Novavax's vaccine revenues haven't soared yet. But if the FDA approves the shot, the odds could change for NVAX stock.